HH-009 for Advanced Liver Cancer with FGF19 Marker
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or inoperable liver cancer confirmed by biopsy or imaging, and your cancer has gotten worse despite prior treatment
- Your tumor has tested positive for the FGF19 marker (a specific protein on cancer cells)
- Your liver function is relatively preserved (Child-Pugh class A or B, meaning a score of 7 or less)
- Your cancer is stage B or C on the BCLC scale (a system doctors use to classify liver cancer)
- You have not received any cancer treatment in the past 4 weeks, and you have never been treated with FGFR inhibitors
- You are between 18 and 75 years old, in generally good health, with a life expectancy of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests two new targeted drugs (ABSK-011 and ABSK043) for people with advanced liver cancer whose tumors have high levels of the FGF19 protein and who have already tried at least one other treatment.
Hear when a new Advanced or Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.